Harvard Bioscience
HBIO
HBIO
103 hedge funds and large institutions have $211M invested in Harvard Bioscience in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
4% more funds holding
Funds holding: 99 → 103 (+4)
0% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 34
38% less call options, than puts
Call options by funds: $21K | Put options by funds: $34K
Holders
103
Holding in Top 10
2
Calls
$21K
Puts
$34K
Top Buyers
| 1 | +$3.84M | |
| 2 | +$2.3M | |
| 3 | +$1.73M | |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$1.27M |
| 5 |
MPAM
Monarch Partners Asset Management
Boston,
Massachusetts
|
+$1.15M |
Top Sellers
| 1 | -$2.82M | |
| 2 | -$1.75M | |
| 3 | -$1.2M | |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$1.19M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$677K |